发明名称 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
摘要 The present invention relates to isolated polynucleotides encoding a cardiovascular associated (CA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease, the polynucleotide is selected from the group comprising:SEQ ID 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for CA gene polypeptide and with or without the CA gene promoter sequence. The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.
申请公布号 AU2003201159(A8) 申请公布日期 2003.07.24
申请号 AU20030201159 申请日期 2003.01.07
申请人 BAYER HEALTHCARE AG 发明人 STEPHAN SCHWERS;UDO STROPP;HARALD KALLABIS
分类号 G01N33/50;A61K31/713;A61K35/12;A61K38/00;A61K45/00;A61P9/00;A61P9/08;A61P9/10;A61P9/12;C07K14/47;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N15/09;C12N15/12;C12P21/02;C12Q1/02;C12Q1/68;G01N33/15;G01N33/53;G01N33/566;G01N33/68;(IPC1-7):C12N15/12 主分类号 G01N33/50
代理机构 代理人
主权项
地址